Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dexmethylphenidate + guanfacine
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy for attention-deficit/hyperactivity disorder (ADHD) that pairs dexmethylphenidate, a stimulant medication, with guanfacine, a non-stimulant alpha-2A adrenergic agonist. This combination has been studied for its potential to provide enhanced therapeutic benefits compared to either agent alone, particularly in children with ADHD.
- Other names
- d-methylphenidate and guanfacinemethylphenidate + guanfacine
02
Targets
DAT (Dopamine plasma membrane transport protein)ADRA2A (α2A)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on dexmethylphenidate + guanfacine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dexmethylphenidate + guanfacine.